Rachel Zolot Schwartz, MBA

Rachel is a seasoned professional with over 15 years of commercial, strategy, and business development experience within the life sciences industry. She has extensive expertise across a diversity of deal structures and a strong track record of innovative deal making from both large pharma and biotech perspectives.

Before joining Volastra, Rachel played a pivotal role in business development at Pfizer, where she led the commercial assessments for all oncology deals, notably including the $11B acquisition of Array BioPharma in 2019 and the $4B partnership with Myovant Biosciences in 2020. Rachel also led global out licensing deals to externalize medicines that had been deprioritized by Pfizer. In addition to business development, she held senior roles in commercial development and marketing, where she played an integral role developing and implementing the launch plan for oral oncology drug, ORGOVYX. She also spent time in Pfizer’s Portfolio Decision Analysis group supporting R& D investment allocation decisions to optimize value and improve productivity across Pfizer’s portfolio. Prior to her tenure at Pfizer, Rachel was a Principal at Trinity Life Sciences Consulting where she focused on licensing & acquisitions, brand strategy and portfolio optimization. She began her career in sales and marketing at Eli Lilly.